New L.B. Bohle Technology Center Advances Development of Continuous Pharmaceutical Processing
Facility in Germany provides space for evaluating continuous pharmaceutical processing equipment.
L.B. Bohle is constructing a technology center next to its service center in Ennigerloh, Germany to provide additional space for developing, testing, and demonstrating continuous-production process equipment for the pharmaceutical industry, the company announced in a press release. Construction started this past August, and the center is expected to open in June 2014.
“Our customers are relying more and more on continuous production,” said company founder Lorenz Bohle, in the press release. “Our technology center will aid in the development of new products that improve the continuous production process because we will be able to visualize entire production lines in one plant using material from wet and dry granulation.”
At the technology center, L.B. Bohle processing experts will work with specialists from the Universities of Dusseldorf and Graz and experts from Siemens to develop new steps for the permanent and interprocess measuring, monitoring, and controlling of the continuous production process. L.B. Bohle will use these developments to produce new equipment and optimize current machinery for use in the pharmaceutical industry.
Source:
L.B. Bohle
Understanding the Variability in Bioburden Test Results in Biomanufacturing
May 7th 2025This article explores the impact of test volume, microbial distribution, and dilution errors on bioburden testing variability. It presents statistical approaches to estimate percentage error and discusses strategies to optimize microbial enumeration techniques in biopharmaceutical quality control.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Trump Directs FDA, EPA to Reduce Regulatory Barriers to Domestic Pharma Manufacturing
May 7th 2025The White House is instructing FDA to increase fees for and inspections of foreign drug manufacturing plants and reduce the time required to approve such sites that will be newly constructed in the US.
Intertek to Expand UK GMP Facility with 6000 Square Feet of Lab and Office Space
May 7th 2025The company said the expansion is in response to globally rising demand for inhaled biologics, which offer distinct advantages in route of administration, but can be challenging products for developers.
